Expanding the Reach of T Cell Engagers in Solid Tumors through pMHC Multi-Targeting

  • Addressing the fundamental challenge of low pMHC copy number and target heterogeneity that limits TCE efficacy in solid tumors through multi-pMHC recognition strategies
  • Demonstrating how engineered TCRs can recognize multiple cancer-restricted pMHCs through shared structural motifs, enabling potent T cell activation at sub-10 pM EC50s while maintaining specificity
  • Establishing comprehensive specificity de-risking approaches using sequence-agnostic, immunopeptidomics-based screening across >13,000 healthy tissue peptides to support broad application across major solid tumor indications